Willemijn C.
- Country
- The Netherlands
- Department
- 2051:Pediatric Medicine
Research Overview
- Phase 3 Open‑Label Single‑Arm Study of Subcutaneous Zodasiran (ARO‑ANG3) in Adolescents With Homozygous Familial Hypercholesterolemia
- Evaluation of Long-term Safety and Tolerability of Inclisiran in Patients with Heterozygous or Homozygous Familial Hypercholesterolemia Post-ORION-16/13 Studies
- Randomized, Double-Blind, Multicenter Study Evaluating Inclisiran Versus Placebo in Pediatric Patients with Heterozygous Familial Hypercholesterolemia
Data & Insights
Has run more than one trial at 12 of 53 partner sites.
Specializations
Pediatric Lipid Disorders
The investigator specializes in treating children with inherited cholesterol disorders, particularly focusing on familial hypercholesterolemia in its various forms.
- Homozygous Familial Hypercholesterolemia (HoFH)
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Early-onset cholesterol management
Primary focus includes treating children aged 2 to 12 years with genetic lipid disorders.
Cardiovascular Prevention
Expertise centers on preventive cardiology in pediatric populations, with particular attention to managing elevated LDL cholesterol levels in young patients.
- Early intervention strategies
- Long-term cholesterol management
- Pediatric lipid-lowering therapies
Specializes in year-long therapeutic approaches for children with inherited cardiovascular conditions.
Pediatric Medicine
The investigator has developed expertise in pediatric therapeutic applications, specifically in managing complex inherited metabolic conditions.
- Age-specific treatment approaches
- Childhood metabolic disorders
- Pediatric drug therapy
Focuses on tailoring treatments for different age groups within the pediatric population.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.